FrancophonIA/ELRC3.0 huggingface dataset:
English: For the full list of all side effects and restrictions with Lusduna, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha u r-restrizzjonijiet b'Lusduna, ara l-fuljett ta' tagħrif.
English: The reference medicine for Lusduna is Lantus.
Maltese: Ilmediċina ta' referenza għal Lusduna hija Lantus.
English: How does Lusduna work?
Maltese: Kif jintuża Lusduna?
English: Because Lusduna is a biosimilar medicine, studies on effectiveness and safety were not needed as these have been well established for insulin glargine.
Maltese: Minħabba li Lusduna huwa mediċina bijosimili, ma kienx hemm bżonn ta' studji dwar l-effikaċja u ssigurtà minħabba li dawn ġew stabbiliti sew għal insulina glargine.
English: Further information on Talzenna can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/talzenna
Maltese: ema.europa.eu/medicines/human/EPAR/talzenna
English: Talzenna is available as capsules (1 mg and 0.25 mg) and the recommended dose is 1 mg once a day.
Maltese: Talzenna jiġi bħala kapsuli (1 mg u 0.25 mg) u d-doża rakkomandata hija 1 mg darba kuljum.
English: Talzenna contains the active substance talazoparib.
Maltese: Talzenna fih is-sustanza attiva talazoparib.
English: Other information about Talzenna
Maltese: Informazzjoni oħra dwar Talzenna
English: The most common side effects with Talzenna (which may affect more than 1 in 4 people) are tiredness, anaemia (low red blood cell counts which can cause tiredness and pale skin), nausea (feeling sick), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), thrombocytopenia (low blood levels of platelets), and headache.
Maltese: L-effetti sekondarji l-aktar komuni b'Talzenna (li jistgħu jaffettwaw aktar minn 1 minn kull 4 minn nies) huma għeja, anemija (għadd baxx taċ-ċelloli ħomor tad-demm li jistgħu jikkawżaw għeja u ġilda ċara), nawżja (tħossok ma tiflaħx), newtropenija (livelli baxxi ta' newtrofili, tip ta' ċellola bajda tad-demm li tiġġieled l-infezzjoni), tromboċitopenija (livelli baxxi ta' pjastrini), u wġigħ ta' ras.
English: What are the risks associated with Talzenna?
Maltese: X'inhuma r-riskji assoċjati ma' Talzenna?
English: The active substance in Talzenna, talazoparib, blocks the action of enzymes called human poly-ADP ribose polymerase (PARP), which are proteins that help to repair damaged DNA in cells (both in normal and in cancer cells) during cell division.
Maltese: Is-sustanza attiva f'Talzenna, it-talazoparib, timblokka l-azzjoni ta' enzimi li jissejħu poli-ADP ribose polimerażi (PARP) tal-bniedem, li huma proteini li jgħinu jsewwu DNA danneġġjata f'ċelloli (kemm f'ċelloli normali kif ukoll f'ċelloli tal-kanċer) waqt id-diviżjoni taċ-ċelloli.
English: How is Talzenna used?
Maltese: Talzenna?
English: As for all medicines, data on the use of Talzenna are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Talzenna hija ssorveljata kontinwament.
English: The side effects with Talzenna were generally well-tolerated and when needed, manageable with dose modifications, and/or standard supportive medical therapy.
Maltese: L-effetti sekondarji b'Talzenna kienu ġeneralment ittollerati tajjeb u fejn meħtieġ, ġestibbli b'modifiki fid-doża, u/jew terapija medika standard ta' appoġġ.
English: Talzenna is a cancer medicine used on its own to treat a type of breast cancer (HER2-negative with BRCA mutations) that has spread beyond the original site, in patients who have been treated with certain medicines which have stopped working or when these medicines are not suitable.
Maltese: Talzenna huwa mediċina tal-kanċer użata waħedha biex tikkura tip ta' kanċer tas-sider (HER2-negattiv b'mutazzjonijiet ta'BRCA) li nfirex lil hinn mis-sit oriġinali, f'pazjenti li ġew ikkurati b'ċerti mediċini li waqfu jaħdmu jew meta dawn il-mediċini ma jkunux xierqa.
English: The most common severe side effects (which may affect more than 1 in 10 people) which led to changes in the dose of Talzenna are anaemia, neutropenia and thrombocytopenia.
Maltese: L-effetti sekondarji severi l-aktar komuni (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 10) li wasslu għal bidliet fid-doża ta' Talzenna huma anemija, newtropenija u tromboċitopenija.
English: Talzenna was shown to be effective at increasing the time patients live without their disease getting worse in one main study involving 431 patients with HER2-negative breast cancer with BRCA mutations whose cancer had spread.
Maltese: Talzenna jista' jinkiseb biss b'riċetta ta' tabib u l-kura għandha tinbeda u tkun issorveljata minn tabib b'esperjenza fl-użu ta' mediċini kontra l-kanċer.
English: For the full list of side effects and restrictions with Talzenna, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet b'Talzenna, ara l-fuljett ta' tagħrif.
English: Further information on Fasenra can be found on the Agency's website: ema.europa.eu/medicines/Human/EPAR/fasenra.
Maltese: Aktar informazzjoni dwar Fasenra tinstab fis-sit web tal-Aġenzija: ema.europa.eu/medicines/Human/EPAR/fasenra.
English: Fasenra received a marketing authorisation valid throughout the EU on 8 January 2018.
Maltese: Fasenra rċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-8 ta' Jannar 2018.
English: Fasenra contains the active substance benralizumab.
Maltese: Fasenra fih is-sustanza attiva l-benralizumab.
English: Other information about Fasenra
Maltese: Informazzjoni oħra dwar Fasenra
English: A third study involving 220 patients showed that more patients given Fasenra had their condition improved to the extent that they could reduce their dose of corticosteroids by an average of 75% compared with 25% of those given placebo.
Maltese: Tielet studju li involva 220 pazjent wera li iktar pazjenti li ngħataw Fasenra tjibietilhom il-kundizzjoni tagħhom sal-punt li setgħu jnaqqsu d-doża tagħhom ta' kortikosterojdi b'medja ta' 75% meta mqabbla ma' 25% ta' dawk li ngħataw plaċebo.
English: Among patients with the highest number of blood eosinophils before treatment, the number of severe flareups per year was 0.66 in patients treated with Fasenra (given every 4 weeks for the first 3 doses and every 8 weeks afterwards), compared with 1.14 in patients given placebo (a dummy treatment).
Maltese: Fost pazjenti bl-ogħla numru ta' eosinofili fid-demm qabel il-kura, in-numru ta' taħrixiet severi fis-sena kien ta' 0.66 f'pazjenti kkurati b'Fasenra (mogħti kull 4 ġimgħat għall-ewwel 3 dożi u mbagħad kull 8 ġimgħat), meta mqabbel ma' 1.14 f'pazjenti li ngħataw plaċebo (kura finta).
English: What are the risks associated with Fasenra?
Maltese: X'inhuma r-riskji assoċjati ma' Fasenra?
English: The active substance in Fasenra, benralizumab, is a monoclonal antibody (a type of protein) designed to attach to receptors (targets) called interleukin-5 receptors on the surface of eosinophils.
Maltese: antikorp monoklonali (tip ta' proteina) mfassla biex tingħaqad ma' riċetturi (miri) msejħa riċetturi talinterlukin-5 fuq is-superfiċje tal-eosinofili.
English: The recommended dose is 30 mg injected under the skin of the thighs or belly every 4 weeks for the first 3 doses, and every 8 weeks afterwards.
Maltese: Id-doża rakkomandata hija ta' 30 mg li għandha tiġi injettata taħt il-ġilda fil-koxxa jew fiż-żaqq kull 4 ġimgħat għall-ewwel 3 dożi, u mbagħad kull 8 ġimgħat.
English: The medicine is well tolerated with few side effects.
Maltese: Il-mediċina hija ttollerata sew b'numru baxx ta' effetti sekondarji.
English: As for all medicines, data on the use of Fasenra are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Fasenra hija ssorveljata kontinwament.
English: Fasenra was shown to reduce the number of exacerbations (flare-ups) of asthma during treatment in 2 main studies involving a total of 2,511 patients with eosinophilic asthma that was not adequately controlled by a combination of high-dose inhaled corticosteroids and long-acting beta-agonists.
Maltese: Dawn listudji involvew total ta' 2,511-il pazjent b'ażma eosinofilika li ma kinitx ikkontrollata b'mod adegwat b'taħlita ta' kortikosterojdi b'doża għolja li jittieħdu man-nifs u beta-agonisti li jdumu jaġixxu.
English: Fasenra is an asthma medicine used to treat adults with a particular type of asthma called eosinophilic asthma.
Maltese: Fasenra huwa tip ta' mediċina kontra l-ażma użata biex tikkura adulti li jbatu minn tip partikolari ta' ażma msejħa ażma eosinofilika.
English: Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Maltese: Ħarsa ġenerali lejn Fasenra u għalfejn huwa awtorizzat fl-UE
English: In eosinophilic asthma, symptoms are associated with having too many of a type of white blood cell called eosinophils in the blood and in phlegm in the lungs.
Maltese: Dan jgħin biex inaqqas l-infjammazzjoni, u b'hekk jirriżulta fi tnaqqis ta' attakki tal-ażma u titjib fis-sintomi.
English: The most common side effects with Fasenra (which may affect up to 1 in 10 people) include headache and pharyngitis (sore throat).
Maltese: L-effetti sekondarji l-aktar komuni b'Fasenra (li jistgħu jaffettwaw sa persuna waħda minn kull 10) huma wġigħ ta' ras u farinġite (uġigħ fil-griżmejn).
English: What measures are being taken to ensure the safe and effective use of Fasenra?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Fasenra?
English: How does Fasenra work?
Maltese: Kif jintuża Fasenra?
English: Fasenra has been shown to be more effective than placebo at reducing the number of asthma flare-ups and the need for corticosteroid treatment.
Maltese: Intwera li Fasenra huwa aktar effettiv minn plaċebo fit-tnaqqis tan-numru ta' taħrixiet tal-ażma u lbżonn għal kura bil-kortikosterojdi.
English: lansoprazole, rabeprazole or omeprazole).
Maltese: lansoprazole, rabeprazole jew omeprazole).
English: • Aggression.
Maltese: • Aggressività.
English: Povidone K-17
Maltese: Linka tal-istampar Povidone K-17
English: Digoxin toxicity has been rarely reported.
Maltese: Tossiċità b'digoxin rarament ġiet osservata.
English: Sugar spheres (sucrose and maize starch) Talc
Maltese: Sugar spheres (sucrose u maize starch) Talc
English: Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, D24 NT20.
Maltese: Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, D24 NT20.
English: • Aggression
Maltese: • Aggressività
English: • Spinning feeling (vertigo).
Maltese: • Sensazzjoni ta' tidwir (vertigo).
English: Naproxen or rofecoxib
Maltese: Naproxen jew rofecoxib
English: Methacrylic acid ethylacrylate copolymer (1:1) dispersion 30 per cent Cellulose microcrystalline
Maltese: Methacrylic acid ethylacrylate copolymer (1:1) dispersjoni 30 fil-mija Cellulose microcrystalline
English: Clopidogrel
Maltese: Clopidigrel
English: An interaction is observed between clopidogrel and esomeprazole.
Maltese: Interazzjoni hija osservata bejn clopidogrel u esomeprazole.
English: Methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent Polysorbate 80
Maltese: Methacrylic acid - ethyl acrylate copolymer (1:1) dispersjoni 30 fil-mija Polysorbate 80
English: Corresponding proportions for esomeprazole 40 mg were 97%, 92% and 56%.
Maltese: Il-proporzjonijiet korrispondenti għal esomeprazole 40 mg kienu 97%, 92% u 56%.
English: Pfizer Consumer Manufacturing Italy S.r.l., Via Nettunense, 90, 04011, Aprilia (LT), Italy.
Maltese: Pfizer Consumer Manufacturing ItalyS.r.l., Via Nettunense, 90, 04011, Aprilia (LT), L-Italja.
English: Date of first authorisation: 26 August 2013 Date of latest renewal: 25 June 2018
Maltese: Data tal-ewwel awtorizzazzjoni: 26 ta' Awwissu 2013 Data tal-aħħar tiġdid: 25 ta' Ġunju 2018
English: Pfizer Gyógyszerkereskedelmi Kft. Consumer Healthcare Tel.: +36 1 488 37 00
Maltese: Kft. Consumer Healthcare Tel.: +36 1 488 37 00
English: • The active substance is esomeprazole.
Maltese: - Is-sustanza attiva hi esomeprazole.
English: Esomeprazole is 97% plasma protein bound.
Maltese: 97% ta' esomeprazole jeħel mal-proteini tal-plażma.
English: Nexium Control contains the active substance esomeprazole.
Maltese: Nexium Control fih is-sustanza attiva esomeprazole.
English: One capsule daily Lasts 24 hours <www.xxx.xxx>
Maltese: Kapsula waħda kuljum Idum 24 siegħa <www.xxx.xxx>
English: Medicinal products metabolised by CYP2C19
Maltese: Prodotti mediċinali metabolizzati b'CYP2C19
English: (Cyprus Pharmaceutical Organization Ltd.)
Maltese: Pfizer Ελλάς Α.Ε. (Cyprus Pharmaceutical Organization Ltd.)
English: dry mouth stomatitis, gastrointestinal candidiasis microscopic colitis
Maltese: ħalq xott stomatite, kandidjasi gastrointestinali kolite mikroskopika
English: Psychiatric disorders insomnia agitation, confusion, depression aggression, hallucinations
Maltese: Disturbi psikjatriċi insomnija aġitazzjoni, konfużjoni, dipressjoni aggressjoni, alluċinazzjoni jiet
English: Skin and subcutaneous tissue disorders dermatitis, pruritus, rash urticaria alopecia, photosensitivity erythema multiforme, StevensJohnson syndrome, toxic epidermal necrolysis (TEN)
Maltese: Disturbi fil-ġilda u fit-tessuti ta' taħt il-ġilda dermatite, ħakk, raxx urtikarja alopeċja, fotosensittività eritema multiforme, sindromu ta' Stevens-Johnson, nekroliżi epidermali tossika (TEN)
English: • The other ingredients are: glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, magnesium stearate, methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent, polysorbate 80, sugar spheres (sucrose and maize starch), talc, triethyl citrate, carmine (E120), indigo carmine (E132), titanium dioxide (E171), yellow iron oxide (E172), erythrosine (E127), allura red AC (E129), povidone K-17, propylene glycol, shellac, sodium hydroxide, and gelatin (see section 2, “Nexium Control contains sucrose”.)
Maltese: - Is-sustanzi l-oħra huma: glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, magnesium stearate, methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 fil-mija, polysorbate 80, sugar spheres (sucrose umaize starch ), talc, triethyl citrate, carmine (E120), indigo carmine (E132),titanium dioxide ( E171), iron oxide isfar (E172), erythrosine (E127), allura red AC (E129), povidone K-17, propylene glycol, shellac, sodium hydroxide, u ġelatina (ara sezzjoni 2, “Nexium Control fih sucrose”.)
English: Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUCτ by 15% and 41%, respectively.
Maltese: Omeprazole (40 mg darba kuljum) żied is-Cmax u l-AUCτ ta' voriconazole (substrat ta' CYP2C19) bi 15% u 41%, rispettivament.
English: Investigated medicinal products with no clinically relevant interaction Amoxicillin and quinidine
Maltese: Prodotti mediċinali investigati bl-ebda interazzjoni klinikament rilevanti Amoxicillin u quinidine
English: Esomeprazole is completely metabolised by the cytochrome P450 system (CYP).
Maltese: Esomeprazole huwa metabolizzat kompletament mis-sistema taċ-ċitokromu P450 (CYP).
English: • They have had previous gastric ulcer or gastrointestinal surgery.
Maltese: • Fil-passat kellhom ulċera gastrika jew operazzjoni gastrointestinali.
English: - The other ingredients are glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, reddish-brown iron oxide (E172), yellow iron oxide (E172), magnesium stearate, methacrylic acid ethylacrylate copolymer (1:1) dispersion 30 per cent, cellulose microcrystalline, synthetic paraffin, macrogol 6000, polysorbate 80, crospovidone (Type A), sodium stearyl fumarate, sugar spheres (sucrose and maize starch), talc, titanium dioxide (E171) and triethyl citrate (see section 2, “Nexium Control contains sucrose”).
Maltese: - Is-sustanzi l-oħra huma glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, iron oxide aħmar fil-kannella (E172), iron oxide isfar (E172), magnesium stearate, methacrylic acid ethylacrylate copolymer (1:1) dispersion 30 fil-mija, cellulose microcrystalline, synthetic paraffin, macrogol 6000, polysorbate 80, crospovidone (Tip A), sodium stearyl fumarate, sugar spheres (sucrose u lamtu tal-qamħirrun), talc, titanium dioxide (E171) u triethyl citrate (ara sezzjoni 2, “Nexium Control fih is-sukrożju”).
English: In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations.
Maltese: Barra minn hekk, il-profil ta' sigurtà huwa simili għal formulazzjonijiet differenti, indikazzjonijiet ta' kura, gruppi ta' età u popolazzjonijiet ta' pazjenti.
English: For 20 mg esomeprazole the corresponding values are 50% and 68% respectively.
Maltese: Għal 20 mg esomeprazole, il-valuri korrispondenti huma 50% u 68% rispettivament.
English: 14 gastro-resistant capsules.
Maltese: 14-il kapsula gastro-reżistenti.
English: In vivo conversion to the R-isomer is negligible.
Maltese: Ilkonverżjoni in vivo għall-isomeru R hija negliġibbli.
English: The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUCt by 280%.
Maltese: Linibitur ta' CYP2C19 u CYP3A4 voriconazole żied l-AUCt ta' omeprazole b'280%.
English: Respiratory, thoracic and mediastinal disorders bronchospasm
Maltese: Disturbi respiratorji, toraċiċi u medjastinali bronkospażmu
English: The reactions are classified according to MedDRA frequency convention: very common (≥ 1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Maltese: Ir-reazzjonijiet huma kklassifikati skont il-konvenzjoni talfrekwenza MedDRA: komuni ħafna (> 1/10); komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000); rari ħafna (<1/10,000); mhux magħruf (ma jistax jiġi stmat mid-dejta disponibbli).
English: • Avoid fizzy drinks, coffee, chocolate and alcohol.
Maltese: • Evita xorb bil-gass, kafè, ċikkulata u alkoħol.
English: • Tacrolimus (in cases of organ transplantation).
Maltese: • Tacrolimus (f'każijiet ta' trapjant tal-organi).
English: • Tacrolimus (in cases of organ transplantation)
Maltese: • Tacrolimus (f'każijiet ta' trapjant tal-organi)
English: • St. John's wort (Hypericum perforatum) (used to treat depression).
Maltese: John's wort (Hypericum perforatum) (użat għall-kura tad-depressjoni).
English: Nexium Control 20 mg Capsules
Maltese: Nexium Control 20 mg Kapsuli
English: Nexium Control contains sucrose
Maltese: Nexium Control fih is-sucrose
English: Esomeprazole is metabolised by CYP2C19 and CYP3A4.
Maltese: Esomeprazole jiġi metabolizzat minn CYP2C19 u CYP3A4.
English: • St. John's wort (Hypericum perforatum) (used to treat depression)
Maltese: John's wort (Hypericum perforatum) (użat għall-kura tad-depressjoni)
English: EU/1/13/860/001 7 gastro-resistant tablets EU/1/13/860/002 14 gastro-resistant tablets
Maltese: EU/1/13/860/001 7 pilloli gastro-reżistenti EU/1/13/860/002 14-il pillola gastro-reżistenti
English: Gastrointestinal disorders abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign)
Maltese: Disturbi gastrointestinali uġigħ addominali, stitikezza, dijarea, gass fl-istonku, nawseja/ rimettar, polipi fil-glandola fundika (beninni)
English: Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.
Maltese: L-għoti konkomitanti ta' 30 mg ta' esomeprazole wassal għal tnaqqis ta' 45% fit-tneħħija tas-substrat ta' CYP2C19 diazepam.
English: • Ketoconazole and itraconazole (used to treat infections caused by a fungus).
Maltese: • Ketoconazole u itraconazole (użati għall-kura ta' infezzjonijiet ikkawżati minn fungu).
English: Both the Rand S-isomer of omeprazole have similar pharmacodynamic activity.
Maltese: Kemm l-isomeru-R u -S ta' omeprazole għandhom attività farmakodinamika simili.
English: The investigators' assessments of heartburn resolution were consistent with the subjects' assessments, showing statistically significant differences between esomeprazole (34.7% - 41.8%) compared to placebo (8.0% - 11.4%).
Maltese: Il-valutazzjonijiet talinvestigaturi ta' solliev minn ħruq ta' stonku kienu konsistenti mal-valutazzjonijiet tal-individwi, u dan juri differenzi statistikament sinifikanti bejn esomeprazole (34.7% - 41.8%) meta mqabbel ma' plaċebo (8.0% - 11.4%).
English: In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4.
Maltese: F'dawn l-individwi l-metaboliżmu ta' esomeprazole huwa probabbilment katalizzat prinċipalment minn CYP3A4.
English: • Severe kidney problems.
Maltese: • Problemi severi fil-kliewi.
English: The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole.
Maltese: Il-parti l-kbira tal-metaboliżmu ta' esomeprazole tiddependi fuq is-CYP2C19 polimorfika, li hija responsabbli għall-formazzjoni tal-metaboliti hydroxy u desmethyl ta' esomeprazole.
English: The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once-daily administration.
Maltese: Ilbijodisponibbiltà assoluta hija ta' 64% wara doża waħda ta' 40 mg u tiżdied għal 89% wara għoti ripetut darba kuljum.
English: • Voriconazole (used to treat infections caused by a fungus) and clarithromycin (used to treat infections).
Maltese: • Voriconazole (użat għall-kura ta' infezzjonijiet ikkawżati minn fungu) u clarithromycin (użat għall-kura ta' infezzjonijiet).
English: Effects of other medicinal products on the pharmacokinetics of esomeprazole Medicinal products which inhibit CYP2C19 and/or CYP3A4
Maltese: Effetti ta' prodotti mediċinali oħra fuq il-farmakokinetika ta' esomeprazole Prodotti mediċinali li jinibixxu CYP2C19 u/jew CYP3A4
English: • Severe kidney problems
Maltese: • Problemi severi fil-kliewi
English: • Atazanavir, saquinavir (used to treat HIV infection).
Maltese: • Atazanavir, saquinavir (użati għall-kura ta' infezzjoni tal-HIV).
English: Nexium Control is available in pack sizes of 7 and 14 gastro-resistant tablets in blisters.
Maltese: Nexium Control huwa disponibbli f'daqsijiet ta' pakketti ta' 7 u 14-il pillola gastro-reżistenti f'folji.
English: One tablet daily Lasts 24 hours
Maltese: Pillola waħda kuljum Idum 24 siegħa
English: Protease inhibitors
Maltese: Inibituri tal-protease
English: Once complete relief of symptoms has occurred, treatment should be discontinued.
Maltese: Ladarba jkun hemm solliev komplet mis-sintomi, il-kura għandha titwaqqaf.
English: Mean peak plasma concentrations were 60% higher.
Maltese: Il-konċentrazzjonijiet massimi medji fil-plażma kienu 60% ogħla.
English: EU/1/13/860/003 14 gastro-resistant capsules
Maltese: EU/1/13/860/003 14-il kapsula gastro-reżistenti
English: Do not take Nexium Control
Maltese: Tiħux Nexium Control
English: Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme.
Maltese: Esomeprazole jinibixxi lil CYP2C19, l-enzim maġġuri li jimmetabolizza lil esomeprazole.
English: • Atazanavir, saquinavir (used to treat HIV infection)
Maltese: • Atazanavir, saquinavir (użati għall-kura ta' infezzjoni tal-HIV)
English: • Rifampicin (used to treat tuberculosis).
Maltese: • Rifampicin (użat għall-kura tat-tuberkulożi).
English: Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg orally daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40%, and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.
Maltese: Riżultati minn studji fuq individwi b'saħħithom urew interazzjoni farmakokinetika (PK)/farmakodinamika (PD) bejn clopidogrel (300 mg doża ta' tagħbija /75 mg doża ta' manteniment ta' kuljum) u esomeprazole (40 mg b'mod orali kuljum) li wasslet għal tnaqqis flespożizzjoni għall-metabolit attiv ta' clopidogrel b'medja ta' 40%, u wasslet għal tnaqqis fl-inibizzjoni massima fl-aggregazzjoni tal-plejtlits (indotta minn ADP) b'medja ta' 14%.
English: • Rifampicin (used to treat tuberculosis)
Maltese: • Rifampicin (użat għall-kura tat-tuberkulożi)